Increased Screening Rates and Diagnostic Testing

The Challenges

There are key challenges facing the improvement of screening and diagnosis in lung cancer

1) Globally, many countries have not yet adopted lung cancer screening despite evidence suggesting that lung cancer screening saves lives.2,3

 

2) Where screening has been adopted, engaging the high risk population remains a challenge meaning too few are screened.10

 

 


3) There remain barriers to accurate and timely lung cancer staging which prevents patients from receiving optimal treatment.6

 



Our solutions

Advancing screening 

The Alliance is helping to amass a global registry of CT imaging data to enhance screening in early-stage lung cancer. This project is part of the Early Lung Imaging Confederation (ELIC), an IASLC-owned, secured, cloud-based archive of shared CT lung cancer images, founded in 2018.11

ELIC could become an important global resource for lung cancer researchers and care teams. The collection of images and data are intended to support development of better analysis and detection tools. They also promise to assist researchers who might only have access to a small number of CT images in their centers can interrogate thousands of images to greatly expand their knowledge base and validate software analysis tools.


Improving Staging

With the support of the Alliance, the IASLC is working to standardize international lung cancer staging guidelines and deepen insights into disease progression. Insights from this effort will inform the 9th Edition of the Tumor, Node and Metastasis (TNM) Staging System, the most common method for staging lung cancer, and guide physicians in identifying the right treatment for the right patient at the right time.12



References

  1. World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed August 2019
  2. EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
  3. Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed May 2019
  4. Yousaf-Khan U, et al. Final Screening Round of the NELSON Lung Cancer Screening Trial: The Effect of a 2.5-year Screening Interval. Thorax. 2017;72:48–56.
  5. The National Lung Screening Trial Research Team. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409.
  6. Midthun D. Early detection of lung cancer. F1000Research. 2016;5(F1000 Faculty Rev):739
  7. NICE. The diagnosis and treatment of lung cancer (update). Available at https://www.ncbi.nlm.nih.gov/books/NBK99021/pdf/Bookshelf_NBK99021.pdf. Accessed August 2019
  8. Mathur S, et al. Personalised medicine could transform health care. Biomed Rep. 2017; (1) 3-5
  9. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  10. Jemal a & Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281
  11. IASLC.org. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at https://www.iaslc.org/news/iaslc-successfully-pilots-early-lung-imaging-confederation-project-0. Accessed August 2019
  12. Giroux, DJ et al. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology. 2018;13(6):801-809
  13. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  14. Mascaux C, et al. Personalised medicine for nonsmall cell lung cancer. European Respiratory Review. 2017;26
  15. IASLC.org. IASLC Pathology Committee. Available at https://www.iaslc.org/research-education/iaslc-pathology-committee. Accessed August 2019